Oral ketamine vs placebo in patients with cancer-related neuropathic pain

Fallon, Marie T.; Wilcock, Andrew; Kelly, Caroline A.; Paul, James; Lewsley, Liz-Anne; Norrie, John; Laird, Barry J. A.

Abstract

Ketamine hydrochloride is used as an adjuvant treatment for cancer-related neuropathic pain, but evidence of its effectiveness is limited.1 Findings of a large trial investigating the use of ketamine for general cancer pain were negative, but the population studied did not specifically have neuropathic pain. A randomized trial of oral ketamine for cancer-related neuropathic pain has been called for, and the present trial addresses that need.

Citation

Fallon, M. T., Wilcock, A., Kelly, C. A., Paul, J., Lewsley, L.-A., Norrie, J., & Laird, B. J. A. (2018). Oral ketamine vs placebo in patients with cancer-related neuropathic pain. JAMA Oncology, 4(6), 870-872. https://doi.org/10.1001/jamaoncol.2018.0131

• Journal Article Type: Article
• Acceptance Date: Jan 11, 2018
• Online Publication Date: Apr 5, 2018
• Publication Date: 2018-06
• Deposit Date: Apr 16, 2018
• Publicly Available Date: Apr 16, 2018
• Journal: JAMA Oncology
• Print ISSN: 2374-2437
• Electronic ISSN: 2374-2445
• Publisher: American Medical Association
• Peer Reviewed: Peer Reviewed
• Volume: 4
• Issue: 6
• Pages: 870-872
• DOI: https://doi.org/10.1001/jamaoncol.2018.0131
• Public URL: https://nottingham-repository.worktribe.com/output/923689
• Publisher URL: https://doi.org/10.1001/jamaoncol.2018.0131
• Contract Date: Apr 16, 2018